Skip to Content

Intercept Pharmaceuticals Inc ICPT Stock Quote

| Rating as of


Morningstar‘s Stock Analysis ICPT

There is no Morningstar’s Analysis data available.

Key Statistics ICPT

Company Profile ICPT

Business Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

10 Hudson Yards, 37th Floor
New York, NY, 10001
T +1 646 747-1000
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 437

Related News ICPT